The past and the future of cancer genetics

Journal of B.U.ON.

Volumn 9, Issue 4, 2004, Pages 347-354

  Janković, Radmila ^a   Brankovic Magic M ^a   Radulovic S ^a  

^a INSTITUTE FOR ONCOLOGY AND RADIOLOGY OF SERBIA   (Serbia)

Author keywords

Cancer epigenetics; Cancer genetics; Gene mutation; Genomic instability; Protooncogenes; Tumor suppressor genes

Indexed keywords

ABELSON KINASE; ADENOVIRUS VECTOR; ANTINEOPLASTIC AGENT; APC PROTEIN; ARF PROTEIN; ATM PROTEIN; BRCA1 PROTEIN; BRCA2 PROTEIN; CHECKPOINT KINASE 2; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FIBROBLAST GROWTH FACTOR; GENOMIC DNA; K RAS PROTEIN; MYC PROTEIN; ONYX 015; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PLATELET DERIVED GROWTH FACTOR; PROTEIN E6; PROTEIN E7; PROTEIN FARNESYLTRANSFERASE; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN MDM2; PROTEIN MLH1; PROTEIN MSH2; PROTEIN P16; PROTEIN P53; RETINOBLASTOMA PROTEIN; TRASTUZUMAB; UNINDEXED DRUG; VASCULOTROPIN; VON HIPPEL LINDAU PROTEIN;

ADENOVIRUS 5; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CANCER GENETICS; CANCER INHIBITION; CANCER PATIENT; CANCER RESEARCH; CARCINOGENESIS; CELL ACTIVATION; CELL PROLIFERATION; CHROMOSOME REARRANGEMENT; CLINICAL PRACTICE; CLINICAL TRIAL; COLORECTAL TUMOR; DNA REPAIR; DRUG EFFICACY; EPIGENETICS; GENE AMPLIFICATION; GENE FUNCTION; GENE MUTATION; GENE REARRANGEMENT; GENETIC REGULATION; GENOMIC INSTABILITY; GENOMICS; GERM LINE; HEAD AND NECK CANCER; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; MALIGNANT NEOPLASTIC DISEASE; MALIGNANT TRANSFORMATION; MUTATION RATE; ONCOGENE H RAS; ONCOGENE N RAS; PROTO ONCOGENE; SIDE EFFECT; SIGNAL TRANSDUCTION; SOMATIC MUTATION; TUMOR GROWTH; TUMOR SUPPRESSOR GENE; UTERINE CERVIX CANCER; VIRAL GENE DELIVERY SYSTEM;

EID: 14044276930     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Bovery T. In Zur Frage der Enstehung Maligner Tumoren. (Gustav Fisher, Jena) 1914; 1-64.
2. Bovery T. Uber mehpolige mitosen als mittel zur analyse des zellkerns. Verh D Phys Med Ges Wurzberg NF 1902; 35: 67-90.
3. Bovery T. Uber die konstitution der chromatischen kernsubstanz. Verh D Zool Ges 1903; 13.
4. Bovery T. Ergebnisse uber die konstitution der chromatischen substanz des zellkens. (Gustav Fisher, Jena) 1904.
5. Bertram JS. The molecular biology of cancer. Mol Asp Med 2001; 21: 167-223.
6. Nowell P, Hungerford D. Chromosomes of normal and leukemic human leucocytes. J Natl Cancer Inst 1960; 25:80.
7. Bishop JM. Enemies within: the genesis of retroviral oncogenes. Cell 1981; 23: 5-6.
8. Graham FL, van der Eb AJ. A new technique for the assay of infectivity of human adenovirus 5 DNA. Virology 1973; 52: 456-467.
9. Graham FL, van der Eb AJ, Heijnher HI. Size and location of the transforming region in human adenovirus type 5 DNA. Nature 1974; 251: 687-691.
10. Shih C, Weinberg RA. Isolation of a transforming sequence from a human bladder carcinoma cell line. Cell 1982; 29: 161-169.
11. Goldfarb M, Shimizu K, Perucho M, Wigler M. Isolation and preliminary characterization of a human transforming gene from T24 bladder carcinoma cells. Nature 1982; 296: 404-409.
12. Rabbits TH. Chromosomal translocations in human cancer. Nature 1994; 372: 143-149.
13. Shields JM, Pruitt K, McFall A, Shaub A, Der CJ. Understanding Ras: "it ain't over'til it's over". Trends Cell Biol 2000; 10: 147-154.
14. Minamoto T. Mai M, Ronai Z et al. K-ras mutation: early detection in molecular diagnosis and risk assessment of colorectal, pancreas, and lung cancers-a review. Cancer Detect Prev 2000; 24: 1-12.
15. Rowinsky EK, Windle JJ, Hoff D et al. Ras protein farnesyl-transferase: a strategic target for anticancer therapeutic development. J Clin Oncol 1999; 17: 3631-3652.
16. Yen L, You XL, AlMoustafa AE et al. Heregulin selectively upregulates vascular endothelial growth factor secretion in cancer cells and stimulate angiogenesis. Oncogene 2000; 19: 3460-3469.
17. Pelengaris S, Khan M. The many faces of c-myc. Arch Biochem Biophys 2003; 416: 129-136.
18. Pelengaris S, Khan M, Evan G. c-myc: more than just a matter of life and death. Nat Rev Cancer 2002; 2: 764-776.
19. Li MJ, Maizels N. Activation and targeting of immunoglobulin switch recombination by activities induced by EBV infection. J Immunol 1999; 163: 6659-6664.
20. Harris H, Miller OJ, Klein G, Worst P, Tachibana T. Suppression of malignancy by cell fusion. Nature 1969; 223: 363-368.
21. Stanbridge EJ. Suppression of malignancy in human cells. Nature 1976; 260: 17-20.
22. Knudson AG. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci USA 1971; 68: 820-823.
23. Knudson AG. Mutation and human cancer. Adv Cancer Res 1973; 17: 317-352.
24. Knudson AG. Two genetic hits (more or less) to cancer. Nat Rev Cancer 2001; 1: 157-162.
25. Noel B, Quack B, Rethore MO. Partial deletions and trisomies of chromosome 13: mapping of bands associated with particular malformations. Clin Genet 1976; 9: 593-602.
26. Kaelin WG Jr. Functions of the retinoblastoma protein. Bioessays 1999; 21: 950-958.
27. Nevins JR. The Rb/E2F pathway and cancer. Hum Mol Genet 2001; 10: 699-703.
28. Trimarchi JM, Lees JA. Sibling rivalry in the E2F family. Nat Rev Mol Cell Biol 2002; 3: 11-20.
29. Munger K. The role of human papilloma viruses in human cancers. Front Biosci 2002; 7: d641-d649.
30. zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2002; 2: 342-350.
31. Li J, Hu SX, Perng GS et al. Expression of the retinoblastoma (Rb) tumor suppressor gene inhibits tumor cell invasion in vitro. Oncogene 1996; 13: 2379-2386.
32. Soussi T, Gallou C, Beroud C. The p53 database. December 2001. (Accessed October 22, 2002, at http://p53.curie.fr.).
33. Harris CC. p53 tumor suppressor gene: from the basic research laboratory to the clinic-an abridged historical perspective. Carcinogenesis 1996; 17: 1187-1198.
34. Lowe SW. Activation of p53 by oncogenes. Endocr Relat Cancer 1999; 6: 45-48.
35. Soussi T, Beroud C. Assessing TP53 status in human tumors to evaluate clinical outcome. Nat Rev Cancer 2001; 1: 233-240.
36. Borresen-Dale AL. TP53 and breast cancer. Hum Mut 2003; 21: 292-300.
37. Oren M, Damalas A, Gottlieb T et al. Regulation of p53: intricate loops and delicate balances. Biochem Pharmacol 2002; 64: 865-871.
38. Clayman GL. The current status of gene therapy. Semin Oncol 2000; 27:39-43.
39. Khuri FR, Nemunaitis J, Ganly I et al. A controlled trial of intratumoral ONYX-15, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med 2000; 6: 879-885.
40. Vasillev LT, Vu BT, Graves B et al. In vivo activation of the p53 pathway by small-molecule antagonists of mdm2. Science 2004; 303: 844-848.
41. Malkin D, Li FP, Strong LC et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 1990; 250: 1233-1238.
42. Lynch HT, de la Chapelle A. Genetic susceptibility to non-polyposis colorectal cancer. J Med Genet 1999; 36: 801-818.
43. Kinzler KW, Vogelstein B. Colorectal tumors. In: Kinzler KW (ed): The Genetic Basis of Human Cancer. McGrawHill, New York, 2002, pp 583-612.
44. Narod SA, Foulkes WD. BRCA1 and BRCA2: 1994 and beyond. Nat Rev Cancer 2004; 4: 665-676.
45. Miky Y, Swensen J, Shattuck-Eldens D et al. A strong candidate for the breast and ovarian cancer susceptibility gene: BRCA1. Science 1994; 266: 66-71.
46. Ford D, Easton DF, Bishop DT et al. Risk of cancer in BRCA1-mutation carriers. Lancet 1994; 343: 692-695.
47. Wooster R, Bignell G, Lancaster J et al. Identification of the breast cancer susceptibility gene BRCA2. Nature 1995; 378: 789-792.
48. Lynch HT, de la Chapelle A. Hereditary colorectal cancer. N Engl J Med 2003; 348: 919-932.
49. Loeb LA, Loeb KR, Anderson JP. Multiple mutations and cancer. Proc Natl Acad Sci USA 2003; 100: 776-781.
50. Balmain A, Gray J, Ponder B. The genetics and genomics of cancer. Nat Genet 2003; 33: 238244.
51. Feinberg AP, Vogelstein B. Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature 1983; 301: 89-92.
52. Feinberg AP, Tycko B. The history of cancer epigenetics. Nat Rev Cancer 2004; 4: 143-153.